TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06179277

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrefGel® + Emdogain®
Description: Surgical crown lengthening procedure with root conditioning with 24% EDTA (PrefGel®) and application of 0.3 mL Emdogain® to root surface with 27-gauge needle

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PrefGel®
Description: Surgical crown lengthening procedure with root conditioning with 24% EDTA (PrefGel®)
Study: NCT03300271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile application for self monitoring
Description: Participants in this group will be introduced to use a mobile application to self record and monitor their life style behaviors. They will be also be provided education same as the control group.

Intervention type: OTHER
Group type: OTHER
Intervention: Education
Description: Participants in this group is provided education. Education includes information of metabolic syndrome, methods to manage lifestyle (diet, physical activity).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile application for personal coaching
Description: Participants in this group will be introduced to use a mobile application. Personal coaches such as dietitian, sports manager encourage to improve their life style behaviors. They will be also be provided education same as the control group.
Study: NCT01281254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG386 plus PLD
Description: AMG 386 is a first in class investigational anti angiogenic drug that provides potent and selective inhibition of angiopoietins. AMG 386 is designed to inhibit angiogenesis by sequestering Ang1 and Ang2, thereby preventing their interaction with the Tie2 receptor. Pegylated Liposomal Doxorubicin (Doxil/Caelyx) is a preparation of doxorubicin in a liposome that contains surface-grafted segments of the hydrophilic polymer methoxypolyethylene glycol associated with prolonged pharmacokinetics of the free drug. PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 15 mg/kg IV weekly (QW)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus PLD
Description: Pegylated Liposomal Doxorubicin (Doxil/Caelyx) is a preparation of doxorubicin in a liposome that contains surface-grafted segments of the hydrophilic polymer methoxypolyethylene glycol associated with prolonged pharmacokinetics of the free drug.~PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 placebo IV weekly (QW)
Study: NCT01928589

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PBI with sequential chemotherapy
Description: 270 cGy x15

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PBI with concurrent chemotherapy
Description: 270 cGy x15 concurrent with chemotherapy of the treating medical oncologist's choice
Study: NCT00585442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcitriol
Description: 1.0 mcg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01151059

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Trivalent subunit inactivated flu vaccine, Formulation 2010-2011
Description: This phase II is performed as a multicenter study site in non-elderly adult and elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated flu vaccine during the vaccination visit, according to the study protocol (follow-up period: till day 22).
Study: NCT03971240

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: evacuation of traumatic acute subdural hematoma
Description: craniotomy will be done with evacuation of the hematoma
Study: NCT01835574

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Conditional cash transfer and cognitive-behavioral aftercare
Description: The intervention combines a 12-week conditional cash transfer (CCT) intervention with 4-weeks of cognitive-behavioral group aftercare (AC) among women who use ATS. CCT includes thrice weekly urine screening for 12 weeks; participants receive $ for ATS-negative screens. Those with 3 negative screens in a week participants receive a cash bonus, which increase per month to mitigate habituation to the CCT reward schedule. Women who complete \>=50% of ATS negative screening visits may participate in a 4-week, cognitive-behavioral AC group delivered immediately after CCT, which includes: 1) experiential group exercises; 2) didactic recovery skills training; 3) meditation and relaxation training; and 4) a ''lucky draw'' which is a form of CCT that provides positive reinforcement for group attendance.
Study: NCT01825486

Intervention type: BEHAVIORAL
Intervention: accidental falls
Study: NCT04599023

Intervention type: DEVICE
Intervention: MSPT
Description: The MS Performance Test (MSPT) software tool and accompanied hardware is an iPad®-based assessment tool, developed via collaboration between Biogen and the Cleveland Clinic Mellen Center, and designed to objectively quantify the major motor, visual and cognitive function data, and quality of life outcomes, associated with MS and related disorders.These assessment modules of the MSPT are self-administered by MS patients at the point of care and incorporate and expand upon previously validated measures of the MSFC.
Study: NCT02376725

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phaco/IOL
Description: Phaco/IOL refers to extracapsular cataract extraction (using phacoemulsification) and intraocular lens implantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phaco/IOL + goniosynechialysis
Description: Phaco/IOL refers to extracapsular cataract ectraction (using phacoemulsification) and intraocular lens implantation. Goniosynechialysis refers to mechanical breaking of peripheral anterior synechiae using a spatula and goniolens to view the drainage angle structures.
Study: NCT01342354

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiation
Description: Escalating Doses of SBRT in periods of three doses over 10 days
Study: NCT01854216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch 1mg / 24 hours
Description: Rotigotine transdermal patch, repeated dose application over 24 hours; 1 mg / 24 hours
Study: NCT02292979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: 6mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: 375mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: 375mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: 1.2 mg/kg
Study: NCT03591471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycosides Of Tripterygium Wilfordii Hook(GTW)
Description: For severe HSPN GTW is 2mg/kg/d for the first 2 weeks , continued with 1.5mg/kg/d (maximum to 90mg/d) for another 2 weeks; For light HSPN GTW is 1.5mg/kg/d(maximum to 90mg/d) for 4 weeks.~Both the 2 types are continued with 1mg/kg/d of GTW for another 4 weeks . Besides,Sulfotanshinone Sodium Injection,Qingrezhixue graunles,Chinese herbs by syndrome differentiation are plused at the same time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfotanshinone Sodium Injection
Description: Intravenous drip of Sulfotanshinone Sodium Injection with the dosage of 1mg/kg/d(maximum to 50mg), combined with 100-250ml 5% Glucose Solution (G.S) for 2 weeks in both the light and serious type of TCM group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese herbs based on syndrome differentiation
Description: For both the light and serious type of HSPN in TCM group,five traditional Chinese medicine patterns of syndrome are classified on the main pathogenesis Blood Stasis: based on Qingre Zhixue granule,for wind-heat complicated with blood stasis, add Forsythia, Honeysuckle,;for blood-heat complicated with blood stasis,add Buffalo horn,Comfrey; for yin deficiency complicated with blood stasis, add Rhizoma anemarrhenae,Cortex phellodendri;for both qi and yin deficiency complicated with blood stasis,add Astragalus, Heterophylla;for damp-heat complicated with blood stasis,add Scutellaria baicalensis,Lalang Grass Rhizome.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone Acetate Tablets
Description: Prednisone Acetate Tablets are necessary for serious HSPN in controlled group,the initial dosage is 2mg/kg/d(maximum to 30mg,4 weeks),continue to reduce the dosage until discontinued（Reduce the dosage at the rate of 5mg every other day in 4-8 weeks，then reduce the dosage at the rate of 5-10mg per week in 8-12weeks）

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benazepril Hydrochloride Tablets
Description: In controlled group, Benazepril Hydrochloride Tablets are used for both the light and serious type with the dosage of 5-10mg/d(10mg/d for children with weight above 30kg) ,12 weeks in total.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Molecular Weight Heparin Calcium Injection
Description: In controlled group,Low Molecular Weight Heparin Calcium Injection are used for both the light and serious type with the dosage of 100u/kg/d by hypodermic injection for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipyridamole Tab 25 MG
Description: In controlled group,Dipyridamole Tab 25 MG are used for both the light and serious type of HSPN with the dosage of 3mg/kg/d ,3 times a day,12 weeks in total.
Study: NCT01854216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch 1mg / 24 hours
Description: Rotigotine transdermal patch, repeated dose application over 24 hours; 1 mg / 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch 2 mg / 24 hours
Description: Rotigotine transdermal patch, repeated dose application over 24 hours; 2 mg / 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch 2 mg / 24 hours
Description: Rotigotine transdermal patch, repeated dose application over 24 hours; 2 mg / 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch 4 mg / 24 hours
Description: Rotigotine transdermal patch, repeated dose application over 24 hours; 4 mg / 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch 4 mg / 24 hours
Description: Rotigotine transdermal patch, repeated dose application over 24 hours; 4 mg / 24 hours
Study: NCT03620578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-EPOCH-R followed by Nivolumab
Description: 5 induction cycles of DA-EPOCH-R protocol, for patient with Deauville imaging response criteria proven complete metabolic response followed with one year Nivolumab consolidation therapy
Study: NCT01986192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Study: NCT03591471

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chinese medicine placebo
Description: In controlled group,take a potential necessary for patients who come to the hospital of TCM to take traditional Chinese medicine in consideration, we add the traditional Chinese medicine placebo in controlled group.
Study: NCT00892853

Intervention type: PROCEDURE
Group type: OTHER
Intervention: CT of the bones
Description: A CT scan will be performed on one arm and one leg for the purpose of acquiring images for this research study.
Study: NCT00872534

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetylsalicylic acid
Description: 325mg once a day for 7 days
Study: NCT04487535

Intervention type: OTHER
Group type: OTHER
Intervention: Cytokine level
Description: Serum cytokine level will be measured before surgery, 72nd after surgery and 6 weeks after surgery
Study: NCT00872534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid
Description: 325mg once a day for 7 days
Study: NCT00612417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of recombinant FVIII/placebo in healthy male subjects treated with TB-402
Description: Administration of recombinant FVIII/placebo in healthy male subjects treated with TB-402

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Administration of recombinant FVIII/placebo in healthy male subjects treated with TB-402
Description: Administration of recombinant FVIII/placebo in healthy male subjects treated with TB-402
Study: NCT00712725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK3207- 2.5 mg
Description: Arm 1: MK3207 2.5 mg taken after migraine onset.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK3207- 5 mg
Description: Arm 2: MK3207 5 mg taken after migraine onset.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK3207- 10 mg
Description: Arm 3: MK3207 10 mg taken after migraine onset.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK3207- 20 mg
Description: Arm 4: MK3207 20 mg taken after migraine onset.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK3207- 50 mg
Description: Arm 5: MK3207 50 mg taken after migraine onset.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK3207- 100 mg
Description: Arm 6: MK3207 100 mg taken after migraine onset.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo (unspecified)
Description: Placebo taken after migraine onset.
Study: NCT01896076

Intervention type: OTHER
Intervention: ultrasound evaluation of caudal space
Description: After induction of general anesthesia, the patients were placed in the lateral position. The ultrasound evaluation include transverse and longitudinal view.~First, investigators place the transducer at the sacral cornua to obtain a transverse view.~In the transverse view, the distance between two cornua and the depth of caudal space at the sacral hiatus were measured. In the longitudinal view, the distance from the skin to the sacrococcygeal membrane and the optimal angles and the safety distance for needle insertion depending on the points of insertions were measured. From the end of dura sac to the sacral hiatus were regarded as safety distance for the needle insertion during caudal block.
Study: NCT00535704

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strong African American Families-Teen Program
Description: 5 week educational program for teens and their caregivers.Each meeting lasts approximately 2 hours.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: FUEL
Description: 5 week educational program for teens and caregivers. Each weekly session lasts approximately 2 hours
Study: NCT04801433

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Boleda Supramolecular Active Zinc Conditioner
Description: Boleda Supramolecular Active Zinc Conditioner (Shanghai Ruizhi Pharmaceutical Technology Co., Ltd.): 30ml/bottle. Once a day for 4 weeks, apply topically to the scalp psoriasis area, gently massage for 15 minutes then rinse off with warm water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capotetriol scalp solution
Description: Capotetriol scalp solution: 30ml/bottle. Two times a day for 4 weeks, topically applied to scalp psoriasis.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Supramolecular Hydrogel
Description: Supramolecular Hydrogel (Shanghai Ruizhi Pharmaceutical Technology Co., Ltd.): 30ml/bottle. Once a day for 4 weeks, apply topically to the scalp psoriasis area, gently massage for 15 minutes then rinse off with warm water.
Study: NCT01766739

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GL-ONC1
Description: Patients will be enrolled in groups of three and individually assessed for safety and dose limiting toxicity (DLT).
Study: NCT01302834

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: 400 mg/m2 IV 5-7 days before IMRT then 250 mg/m2 IV weekly for 7 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: 100 mg/m2 IV on days 1 and 22 of IMRT
Study: NCT04588948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept
Description: Two arms (non-vitrectomized, and vitrectomized) are included in the study to evaluate the effect of vitrectomy on the intraocular and systemic pharmacokinetics of intravitreal aflibercept injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept
Description: Two arms (non-vitrectomized, and vitrectomized) are included in the study to evaluate the effect of vitrectomy on the intraocular and systemic pharmacokinetics of intravitreal aflibercept injection
Study: NCT01174303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Each subject will be randomly allocated to two single doses injected subcutaneously (under the skin) of insulin degludec/insulin aspart and biphasic insulin aspart 30 in random order.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Each subject will be randomly allocated to two single doses injected subcutaneously (under the skin) of insulin degludec/insulin aspart and biphasic insulin aspart 30 in random order.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Each subject will be randomly allocated to two single doses injected subcutaneously (under the skin) of insulin degludec/insulin aspart and biphasic insulin aspart 30 in random order.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Each subject will be randomly allocated to two single doses injected subcutaneously (under the skin) of insulin degludec/insulin aspart and biphasic insulin aspart 30 in random order.
Study: NCT00438698

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index diet
Description: Diet to emphasize carbohydrate foods low in glycemic index

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Cereal Fibre Diets
Description: Diet to emphasize whole wheat carbohydrate cgoices
Study: NCT05346471

Intervention type: DEVICE
Group type: OTHER
Intervention: Multimodal neuromonitoring
Description: Multimodal neuromonitoring accounts for intraparenchymatous ICP probe, brain tissue oxygen probe and/or cerebral microdialysis device
Study: NCT01302834

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Description: 35 fractions over 6 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 70 Gy.
Study: NCT04522908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib Oral Tablet
Description: Cabozantinib starting dose of 40 mg, oral, once daily for 4 weeks followed by Cabozantinib escalated dose of 60 mg, oral, once daily from week 5 onwards
Study: NCT03718585

Intervention type: OTHER
Intervention: whole exome sequencing analysis
Description: Collecting peripheral blood samples (2 ml) from subjects for whole exome sequencing

Intervention type: OTHER
Intervention: whole exome sequencing analysis
Description: Collecting peripheral blood samples (2 ml) from subjects for whole exome sequencing

Intervention type: OTHER
Intervention: whole exome sequencing analysis
Description: Collecting peripheral blood samples (2 ml) from subjects for whole exome sequencing
Study: NCT03839940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given as mouthwash

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given as mouthwash

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Standard of care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Everolimus
Description: Standard of care
Study: NCT03269994

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefoxitin
Description: Participants will receive one dose of cefoxitin within 1 hour of incision time, redosed every 2-4 hours in the operating room until closure of the incision, and discontinued within 24 hours after anesthesia end time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam
Description: Participants will receive one dose of piperacillin-tazobactam within 1 hour of incision time, redosed every 2-4 hours in the operating room until closure of the incision, and discontinued within 24 hours after anesthesia end time.
Study: NCT03337958

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ventilatory re-education
Description: The first day of intervention consisted primarily in ventilatory re-education. During the realization of the technique he was videotaped with a Tablet so that later the patient could be seen and on the video to be able to give him the guidelines for the correction. On the second and third day of the intervention, ventilation re-education was performed and the inhalation technique was subsequently trained.
Study: NCT00827437

Intervention type: OTHER
Group type: OTHER
Intervention: Parent Interview
Description: To include the PI, Nursing Research Specialist,Clinical Research Associate or Clinical Nurse Specialist
Study: NCT03760185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine Tartrate
Description: All subjects will apply brimonidine tartrate to one eye (right eye) only for the duration of study participation.
Study: NCT02064985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhibition of Platelet Aggregation by Brilinta(Ticagrelor)
Description: To determine the Inhibition of Platelet Aggregation (IPA) profiles of single and multiple doses of ticagrelor 45, 60, and 90 mg in Chinese patients with stable coronary heart disease (CHD) on chronic low dose ASA (75-100mg daily).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhibition of Platelet Aggregation by Brilinta(Ticagrelor)
Description: To determine the Inhibition of Platelet Aggregation (IPA) profiles of single and multiple doses of ticagrelor 45, 60, and 90 mg in Chinese patients with stable coronary heart disease (CHD) on chronic low dose ASA (75-100mg daily).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhibition of Platelet Aggregation by Brilinta(Ticagrelor)
Description: To determine the Inhibition of Platelet Aggregation (IPA) profiles of single and multiple doses of ticagrelor 45, 60, and 90 mg in Chinese patients with stable coronary heart disease (CHD) on chronic low dose ASA (75-100mg daily).
Study: NCT04228835

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fluorescence Cholangiography
Description: Administration of ICG for fluorescence cholangiography
Study: NCT02837848

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coactivation Strengthening
Description: Coactivation strengthening implies a recruitment of the pectoralis major and the latissimus dorsi while performing regular strengthening.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regular Strengthening
Description: Regular strengthening implies external rotation, internal rotation, flexion and abduction of the gleno-humeral joint and scapular protraction and retraction of the scapulothoracic joint strengthening.